@article{fdi:010064703,
  title = {{C}omparative assessment of transmission-blocking vaccine candidates against {P}lasmodium falciparum},
  author = {{K}apulu, {M}. {C}. and {D}a, {D}. {F}. and {M}iura, {K}. and {L}i, {Y}. and {B}lagborough, {A}. {M}. and {C}hurcher, {T}. {S}. and {N}ikolaeva, {D}. and {W}illiams, {A}. {R}. and {G}oodman, {A}. {L}. and {S}angare, {I}. and {T}urner, {A}. {V}. and {C}ottingham, {M}. {G}. and {N}icosia, {A}. and {S}traschil, {U}. and {T}suboi, {T}. and {G}ilbert, {S}. {C}. and {L}ong, {C}. {A}. and {S}inden, {R}. {E}. and {D}raper, {S}. {J}. and {H}ill, {A}. {V}. {S}. and {C}ohuet, {A}nna and {B}iswas, {S}.},
  editor = {},
  language = {{ENG}},
  abstract = {{M}alaria transmission-blocking vaccines ({TBV}s) target the development of {P}lasmodium parasites within the mosquito, with the aim of preventing malaria transmission from one infected individual to another. {D}ifferent vaccine platforms, mainly protein-in-adjuvant formulations delivering the leading candidate antigens, have been developed independently and have reported varied transmission-blocking activities ({TBA}). {H}ere, recombinant chimpanzee adenovirus 63, {C}h{A}d63, and modified vaccinia virus {A}nkara, {MVA}, expressing {A}g{APN}1, {P}fs230-{C}, {P}fs25, and {P}fs48/45 were generated. {A}ntibody responses primed individually against all antigens by {C}h{A}d63 immunization in {BALB}/c mice were boosted by the administration of {MVA} expressing the same antigen. {T}hese antibodies exhibited a hierarchy of inhibitory activity against the {NF}54 laboratory strain of {P}. falciparum in {A}nopheles stephensi mosquitoes using the standard membrane feeding assay ({SMFA}), with anti-{P}fs230-{C} and anti-{P}fs25 antibodies giving complete blockade. {T}he observed rank order of inhibition was replicated against {P}. falciparum {A}frican field isolates in {A}. gambiae in direct membrane feeding assays ({DMFA}). {TBA} achieved was {I}g{G} concentration dependent. {T}his study provides the first head-to-head comparative analysis of leading antigens using two different parasite sources in two different vector species, and can be used to guide selection of {TBV}s for future clinical development using the viral-vectored delivery platform.},
  keywords = {{BURKINA} {FASO}},
  booktitle = {},
  journal = {{S}cientific {R}eports},
  volume = {5},
  numero = {},
  pages = {art. 11193 [15 p.]},
  ISSN = {2045-2322},
  year = {2015},
  DOI = {10.1038/srep11193},
  URL = {https://www.documentation.ird.fr/hor/fdi:010064703},
}